Euformatics and Síntese Biotecnologia partner for sales channel agreement in Latin America

Euformatics, a world-leader in NGS data quality control applications and variant interpretation solutions, has signed a joint market engagement agreement with Síntese Biotecnologia (Síntese) to spearhead its expansion into the Latin American NGS market.

The move comes as part of Euformatics’ renewed strategy to grow its business globally in new markets, with particular focuses on Latin America and South East Asia. These markets are already showing strong signs of growth around NGS technologies, highlighting the need for flexible and comprehensive software tools to enable a smooth transition to wide-spread adoption of NGS-based techniques.

“We are very excited to be taking this first step into growing our customer base in the Latin American market by entering into this partnership with Síntese in Brazil. Working with Síntese as an agent to open doors for us in their well established and broad customer base puts us in a great position to form new relationships and demonstrate the value of our tools to customers in the region. Síntese already has an excellent reputation and track-record of sales in Brazil, and we are looking forward to expanding on these successes together to bring our NGS tools to a market which is expanding at a rapid rate” explained Tommi Kaasalainen, Euformatics CEO.

“The Euformatics offering comes at the right time for the Brazilian market, as NGS takes off and more hospitals and laboratories are looking for the right solution to make their processes simpler. OmnomicsNGS makes variant annotation and reporting easy through its flexible workflows, while omnomicsQ ensures that proper quality control is an integrated part of any NGS lab’s processes. Combined with the expertise Euformatics has in software and genetics they are also able to offer a great level of support. We are convinced that the agreement between us will prove to be very fruitful” emphasised Síntese Business Director, Henrique Vinagre.

The agreement covers the omnomics Suite of genomic data software solutions, including world-leading quality control tool omnomicsQ, as well as its CE-marked variant interpretation and reporting tool, omnomicsNGS.

About Síntese:

Síntese Biotecnologia is a Brazilian company specialized in representing and distributing products and solutions for the Life Science area, serving from researchers, clinical analysis laboratories, public and private health agents.

With more than a decade of history, Síntese Biotecnologia established long-term partnerships with companies recognized worldwide, market leaders in their segments, working according to the most rigorous international quality standards. The company has expanded its prominence connecting the biggest players in the Brazilian health market to crucial biomolecular inputs to tackle the Covid-19 pandemic unleashed in 2020.
https://sintesebiotecnologia.com.br/

About Euformatics:

Euformatics is a Finnish software company that specialises in high standard bioinformatics tools for genomic data interpretation, with the mission to accelerate the transition to precision medicine. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories understand vast amounts of data to better fight cancer, common or rare diseases. At present, our core solution is the omnomics Suite which includes omnomicsNGS; for clinical analysis of patient NGS data, and omnomicsQ; for NGS data quality management.
www.euformatics.com